Randomized multicentre pilot study of LCZ696 versus irbesartan in patients with chronic kidney disease: UK Heart And Renal Protection (HARP)-III
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2018
Price : $35 *
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Irbesartan
- Indications Renal failure
- Focus Therapeutic Use
- Acronyms UK HARP-III
- Sponsors Novartis
- 12 Jul 2018 Primary endpoint (measured GFR (mGFR) at 12 months ) has not been met, according to results published in the Circulation.
- 12 Jul 2018 Results published in the Circulation.
- 19 Sep 2016 Trial rationale, trial design and baseline data (n=414) published in the Nephrology Dialysis Transplantation.